Form 4: Amgen VP of Finance Acquires Shares and Stock Options

Matthew C. Busch, VP of Finance & CAO at Amgen, reports acquisition of common stock and stock options.

Summary

• Matthew C. Busch, VP of Finance & CAO at Amgen, filed a Form 4 detailing changes in beneficial ownership.
• On May 6, 2025, Busch acquired 554 shares of Amgen common stock.
• These shares were granted as Restricted Stock Units (RSUs) under the company's Equity Incentive Plan.
• The RSUs vest in four equal annual installments of 25%, starting May 6, 2026.
• Vested RSUs will be paid in shares of Amgen common stock on a one-to-one basis.
• Busch also acquired 3,585 non-qualified stock options with an exercise price of $270.44.
• These options also vest in four equal annual installments of 25%, commencing on May 6, 2026.
• The options expire on May 6, 2035.
• Busch also owns 4,588 shares of common stock, including 93 Dividend Equivalents (DEs).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing and doesn't inherently convey positive or negative sentiment. It simply reports transactions by a company insider.

Positives

• The acquisition of shares and stock options by a high-ranking officer could be interpreted as a positive signal about the company's future prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a multi-year commitment by the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used by companies like Gilead Sciences, Biogen, and Regeneron to align management's interests with those of shareholders.
• The vesting schedules described in the document (25% per year over four years) are typical for such grants.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders by slightly increasing the number of outstanding shares as RSUs vest and options are exercised.

Key Dates

Keywords

Form 4, Amgen, Stock Options, Restricted Stock Units, Beneficial Ownership, Matthew C. Busch, Equity Incentive Plan